RT Journal Article
SR Electronic
T1 Sero-prevalence Findings from Metropoles in Pakistan: Implications for Assessing COVID-19 Prevalence and Case-fatality within a Dense, Urban Working Population
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.13.20173914
DO 10.1101/2020.08.13.20173914
A1 Javed, Wajiha
A1 Baqar, Jaffer Bin
A1 Abidi, Syed Hussain Baqar
A1 Farooq, Wajiha
YR 2020
UL http://medrxiv.org/content/early/2020/08/14/2020.08.13.20173914.abstract
AB Population-level serologic testing has demonstrated groundbreaking results in monitoring the prevalence and case-fatality of COVID-19 within a population. In Pakistan, Getz Pharma conducted a sero-prevalence survey on a sample of 24,210 individuals using the IgG/IgM Test Kit (Colloidal gold) with follow-up and sequential testing after every 15-20 days on a sub-sample. This is the first of its kind, large scale census conducted on a dense, urban, working population in Pakistan. The study results reveal that from 24,210 individuals screened, 17.5% tested positive, with 7% IgM positive, 6.0% IgG positive and 4.5% combined IgM and IgG positive. These findings have been extrapolated to the rest of the urban, adult, working population of Pakistan, and as of 6th July, 2020, 4.11 million people in Pakistan have been infected with COVID-19, which is 17.7 times higher than the current number of 231,818 symptom-based PCR cases reported by the government which exclude asymptomatic cases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNone to declare.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee from AEIRC Pakistan has duly approved the study protocol.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe assure that all data captured and presented herein, shall be available as and when needed.